3 Key Takeaways
Plain English Summary- 01Core Finding
Histone methylation was once considered a static modification until the discovery of the histone lysine demethylase LSD1 (KDM1A), more than two decades ago.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
What This Means for You
As we enter the third decade of investigations into histone demethylation, unlocking the full therapeutic potential of inhibiting KDMs will require a deeper understanding of their biology, substrate specificity, interaction networks and regulatory crosstalk. We describe the landscape of KDM inhibitors, especially LSD1 inhibitors, which are the most advanced demethylase inhibitors in clinical trials. We highlight the need for more potent and selective KDM inhibitors, biomarkers of therapeutic response, novel combinatorial treatments and innovative drug discovery strategies.
The Discovery
Histone post-translational modifications, such as methylation, acetylation, phosphorylation and ubiquitination, have fundamental roles in regulating chromatin structure and gene expression. Histone methylation was once considered a static modification until the discovery of the histone lysine demethylase LSD1 (KDM1A), more than two decades ago. Since then, numerous KDMs in two main enzyme classes have been identified. Their diverse roles in regulating gene expression, metabolism, immune responses and disease pathogenesis have been extensively studied and small-molecule inhibitors have been developed. KDMs exert context-dependent functions as either oncogenes or tumour suppressors, which complicates their therapeutic targeting.
How It Works, Simply
This pharmacology research focuses on immune response · Enzyme · Blood biomarker (measurable biological signal). Researchers evaluated it using an observational cohort study at the real-world cohort stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Histone methylation was once considered a static modification until the discovery of the histone lysine demethylase LSD1 (KDM1A), more than two decades ago.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
Biological Mechanism & Study Design
Study Design & Cohort
Observational cohort study
Observational cohort study · Real-World Cohort
Biological Pathway & Modality
Immune response · Enzyme · Blood biomarker
Intervention: Histone lysine demethylases in the third decade: biology and therapeutic prospects
Experimental Findings & Endpoints
Histone post-translational modifications, such as methylation, acetylation, phosphorylation and ubiquitination, have fundamental roles in regulating chromatin structure and gene expression.
Histone methylation was once considered a static modification until the discovery of the histone lysine demethylase LSD1 (KDM1A), more than two decades ago. Since then, numerous KDMs in two main enzyme classes have been identified.
Their diverse roles in regulating gene expression, metabolism, immune responses and disease pathogenesis have been extensively studied and small-molecule inhibitors have been developed. KDMs exert context-dependent functions as either oncogenes or tumour suppressors, which complicates their therapeutic targeting.
Clinical Translation & Practice Context
As we enter the third decade of investigations into histone demethylation, unlocking the full therapeutic potential of inhibiting KDMs will require a deeper understanding of their biology, substrate specificity, interaction networks and regulatory crosstalk.
We describe the landscape of KDM inhibitors, especially LSD1 inhibitors, which are the most advanced demethylase inhibitors in clinical trials. We highlight the need for more potent and selective KDM inhibitors, biomarkers of therapeutic response, novel combinatorial treatments and innovative drug discovery strategies.
The Bottom Line · Clinical Pearl
“We highlight the need for more potent and selective KDM inhibitors, biomarkers of therapeutic response, novel combinatorial treatments and innovative drug discovery strategies.”
Published in Nature Reviews Drug Discovery · Current Stage: Real-World Cohort